Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NRBO

NeuroBo Pharmaceuticals Inc

Sep 16 • 02:45PM ET

3.53

Dollar change -0.08
Percentage change -2.22	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF VTI DFAS DFAT

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.97	Insider Own	65.19%	Shs Outstand	4.91M	Perf Week	-14.11%
Market Cap	29.97M	Forward P/E	-	EPS next Y	-1.38	Insider Trans	85.10%	Shs Float	2.95M	Perf Month	-9.49%
Income	-25.90M	PEG	-	EPS next Q	-0.82	Inst Own	12.25%	Short Float	0.95%	Perf Quarter	-7.35%
Sales	0.00M	P/S	-	EPS this Y	-81.30%	Inst Trans	-19.54%	Short Ratio	0.50	Perf Half Y	-23.26%
Book/sh	2.30	P/B	1.53	EPS next Y	69.06%	ROA	-89.41%	Short Interest	0.03M	Perf Year	-2.87%
Cash/sh	3.29	P/C	1.07	EPS next 5Y	-	ROE	-117.35%	52W Range	2.90 - 6.75	Perf YTD	-4.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	69.13%	ROI	-136.02%	52W High	-47.70%	Beta	-0.28
Dividend TTM	-	Quick Ratio	2.94	Sales past 5Y	0.00%	Gross Margin	-	52W Low	21.72%	ATR (14)	0.36
Dividend Ex-Date	-	Current Ratio	2.94	EPS Y/Y TTM	83.52%	Oper. Margin	0.00%	RSI (14)	44.89	Volatility	12.46% 9.41%
Employees	8	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	16.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-1176.22%	Payout	-	Rel Volume	1.15	Prev Close	3.61
Sales Surprise	-	EPS Surprise	-30.28%	Sales Q/Q	-	Earnings	Aug 14 BMO	Avg Volume	55.99K	Price	3.53
SMA20	-2.35%	SMA50	-11.20%	SMA200	-13.47%	Trades		Volume	52,924	Change	-2.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-15-20	Initiated	H.C. Wainwright	Buy	$20

Sep-03-24 08:01AM	NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-14-24 08:01AM	NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
04:32AM	NeuroBo concludes subject enrolment in SAD portion of obesity treatment trial (Clinical Trials Arena)
Aug-13-24 08:01AM	NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire)
Aug-06-24 08:01AM	NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity (PR Newswire) +7.35%
08:01AM	Loading…
Jul-30-24 08:01AM	NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 (PR Newswire)
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-11-24 08:01AM	NeuroBo Pharmaceuticals to Present at the Emerging Growth Conference in July (PR Newswire)
Jun-27-24 06:53AM	NeuroBo doses first subject in Part 2 of Phase I obesity treatment trial (Clinical Trials Arena)
Jun-26-24 09:06AM	NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire) +13.38%
Jun-25-24 05:08PM	NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Jun-24-24 08:01AM	NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (PR Newswire)
Jun-22-24 08:01AM	NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models (PR Newswire)
May-22-24 08:01AM	NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone (PR Newswire) -5.24%
01:53PM	Loading…
May-09-24 01:53PM	NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
08:01AM	NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Apr-30-24 08:01AM	NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June (PR Newswire)
Apr-17-24 08:05AM	NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire)
Apr-01-24 08:01AM	NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire)
Mar-28-24 08:01AM	NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update (PR Newswire) -5.76%
Mar-13-24 08:01AM	NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire) -8.21%
Mar-04-24 08:01AM	NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer (PR Newswire)
Feb-29-24 08:01AM	NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity (PR Newswire) +13.09%
Feb-12-24 08:01AM	NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference (PR Newswire) +9.65%
Feb-01-24 08:01AM	NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity (PR Newswire) +67.28%
Jan-18-24 08:01AM	NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH (PR Newswire)
Jan-09-24 08:30AM	NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement (PR Newswire)
Jan-02-24 08:01AM	NeuroBo to Participate in Industry and Investor Conferences in January (PR Newswire) +11.24%
Dec-28-23 08:45AM	NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity (PR Newswire) +21.23%
08:43AM	Loading…
Dec-19-23 08:43AM	NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split (PR Newswire) -23.55%
Dec-15-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Dec-12-23 01:02PM	Life Science Investor Forum Agenda Announced for December 14th, 2023 (GlobeNewswire)
Dec-01-23 08:31AM	NeuroBo to Participate in Investor Conferences in December (PR Newswire)
Nov-13-23 04:05PM	NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire)
Nov-06-23 08:05AM	NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D. (PR Newswire)
Oct-17-23 08:01AM	NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference (PR Newswire)
Sep-15-23 08:01AM	NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH (PR Newswire) +18.80%
Aug-14-23 08:01AM	NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT (PR Newswire)
Aug-09-23 04:05PM	NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire) +13.13%
Aug-03-23 08:01AM	NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH (PR Newswire) -6.16%
Aug-02-23 08:01AM	NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01 (PR Newswire) +10.89%
Jun-27-23 08:01AM	NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models (PR Newswire) +23.05%
Jun-13-23 08:01AM	NeuroBo Pharmaceuticals Announces Acceptance of Two General Posters and One ePoster Theater Discussion of its Novel GLP1R and GCGR Dual Agonist, DA-1726, at the American Diabetes Association 83rd Scientific Sessions (PR Newswire)
May-12-23 08:00AM	NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors (PR Newswire)
May-02-23 08:01AM	NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH (PR Newswire) -9.08%
Apr-03-23 08:00AM	NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH (PR Newswire)
Mar-30-23 04:40PM	NeuroBo Pharmaceuticals Reports Full Year 2022 Financial Results (PR Newswire)
Jan-18-23 08:00AM	NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President (PR Newswire)
Nov-08-22 04:05PM	NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT (PR Newswire) -42.13% +29.60%
Nov-04-22 09:15AM	NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT (PR Newswire) -44.11%
Sep-29-22 08:30AM	NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria (PR Newswire) -6.15%
Sep-15-22 08:30AM	NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A's Cardio-Metabolic Therapies (PR Newswire) +47.21%
Sep-12-22 09:15AM	NeuroBo Pharmaceuticals Announces Reverse Stock Split (PR Newswire) +101.30%
May-06-22 08:00AM	NeuroBo Pharmaceuticals, Inc. Expands Management Team with the Appointment of Matthew Bardin, PharmD, BCPS as Senior Vice President Operations (PR Newswire)
Apr-01-22 08:00AM	NeuroBo Pharmaceuticals Reports Full Year 2021 Financial Results (PR Newswire)
Mar-15-22 08:00AM	NeuroBo Pharmaceuticals, Inc. Expands Scientific Advisory Board with Appointment of Danamarie Belpulsi, M.D. (PR Newswire) +6.54%
Jan-28-22 04:30PM	NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors (PR Newswire)
Nov-15-21 08:00AM	NeuroBo Pharmaceuticals Reports Third Quarter 2021 Financial Results (PR Newswire)
Nov-04-21 08:00AM	NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer (PR Newswire)
Oct-13-21 08:00AM	NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID-19 (PR Newswire) +6.52%
Oct-05-21 01:13PM	NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering (PR Newswire) -7.17%
Oct-01-21 08:00AM	NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering (PR Newswire) -32.80%
Sep-03-21 11:27AM	Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like (Simply Wall St.) -7.52%
Aug-16-21 08:00AM	NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results (PR Newswire)
Jul-12-21 08:30AM	NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors (PR Newswire)
May-17-21 05:02PM	NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results (PR Newswire) +5.56%
Apr-15-21 04:52PM	NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update (PR Newswire) -12.47%
Mar-24-21 08:00AM	NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene (PR Newswire)
Mar-05-21 08:30AM	NeuroBo Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference (PR Newswire)
Jan-21-21 04:05PM	NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement (PR Newswire)
Jan-19-21 08:00AM	NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement (PR Newswire) -13.93%
Jan-06-21 08:30AM	NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program (PR Newswire) +19.93%
Dec-21-20 05:08AM	Is NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) Popular Amongst Insiders? (Simply Wall St.)
Nov-13-20 04:30PM	NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results (PR Newswire)
Sep-02-20 08:30AM	NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors (PR Newswire)
Aug-11-20 03:00PM	NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results (PR Newswire) -8.40%
Jun-16-20 04:05PM	NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes (PR Newswire)
May-26-20 08:30AM	NeuroBo Pharmaceuticals Announces Continuation of Partial Clinical Hold of Gemcabene (PR Newswire) -5.31%
May-20-20 04:29PM	NeuroBo Pharmaceuticals Reports First Quarter 2020 Financial Results (PR Newswire) -5.10%
Apr-21-20 08:30AM	NeuroBo Pharmaceuticals Announces Issuance of U.S. Patent, Providing Broad Coverage of NB-02 for Neurodegenerative Disorders (PR Newswire)
Apr-16-20 04:22PM	NeuroBo Pharmaceuticals Announces Closing of $7.5 Million Registered Direct Offering (PR Newswire) -17.06% +5.70%
Apr-14-20 09:15AM	NeuroBo Pharmaceuticals Announces $7.5 Million Registered Direct Offering (PR Newswire) -43.27%
Mar-31-20 11:04AM	NeuroBo Pharmaceuticals (NASDAQ:NRBO) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) +7.50%
Mar-30-20 04:30PM	NeuroBo Pharmaceuticals Reports Year End 2019 Financial Results and Provides Corporate Strategic Update (PR Newswire) -11.26%
Jan-13-20 09:00AM	NeuroBo Pharmaceuticals to Present at Biotech Showcase 2020 in San Francisco (Business Wire) -9.40%
Jan-10-20 05:00PM	NeuroBo Pharmaceuticals and Gemphire Therapeutics Complete Merger (Business Wire)

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DONG-A ST CO., LTD	10% Owner	Jun 23 '24	Buy	3.13	2,544,530	7,964,379	5,348,229	Jun 25 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRBO

NeuroBo Pharmaceuticals Inc

Upgrade your FINVIZ experience